Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can extra antibodies shield myeloma patients from infections during powerful new treatment?

NCT ID NCT07094048

First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 18 times

Summary

This study looks at multiple myeloma patients who are receiving a type of immunotherapy called a BCMA-directed T cell engager. These treatments can weaken the immune system and raise the risk of serious infections. The trial will compare two levels of immunoglobulin (antibody) support to see if a lower target is as good as the standard higher target at preventing severe infections over three months. About 80 adults who have had at least one prior treatment and are starting this immunotherapy will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Intégré de Cancérologie

    RECRUITING

    Québec, Quebec, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.